高级别神经胶质瘤是一种侵袭性脑肿瘤，预后较差。了解影响其进展的因素对于改善治疗结果至关重要。本研究探讨了全免疫炎症对于诊断为高级别胶质瘤的患者的预后意义。对 89 例高级别胶质瘤患者的数据进行了回顾性分析。根据治疗第一天采集的外周血样本中获得的血小板、单核细胞、中性粒细胞和淋巴细胞计数，计算符合资格标准的每位患者的全免疫炎症值（PIV）。 PIV 使用以下公式计算：PIV = T × M × N ÷ L。采用受试者操作特征 (ROC) 分析来确定 PIV 关于无进展生存期 (PFS) 和总生存期的最佳截止值 ( OS）结果。主要和次要终点是 PIV 组之间 OS 和 PFS 的差异。采用Kaplan-Meier法进行生存分析。ROC分析表明最佳PIV阈值为545.5，与PFS和OS结果存在显着的交互作用。随后根据患者的 PIV 水平将患者分为两组：由 45 名患者组成的低 PIV (L-PIV) 组和由 44 名患者组成的高 PIV (H-PIV) 组。生存率的比较分析表明，与低 PIV 组的 8.0 个月相比，PIV 升高的患者的中位无进展生存期 (PFS) 较短，为 4.0 个月 (P = 0.797)，并且与未获得的患者相比，中位 OS 减少了 19.0 个月 (NA) ）在低 PIV 组中（P = 0.215）。我们的研究结果并未揭示 H-PIV 测量值与降低的 PFS 或 OS 之间存在统计学上的显着关联。然而，PIV 有效地将新诊断的高级别胶质瘤患者分为两个不同的组，这两个组的 PFS 和 OS 结果显着不同。© 2024。作者获得 Federación de Sociedades Españolas de Oncología (FESEO) 的独家许可。

High-grade gliomas are aggressive brain tumors with poor prognoses. Understanding the factors that influence their progression is crucial for improving treatment outcomes. This study investigates the prognostic significance of panimmune inflammation in patients diagnosed with high-grade gliomas.Data from 89 high-grade glioma patients were analysed retrospectively. The Panimmune inflammation Value (PIV) of each patient meeting the eligibility criteria was calculated on the basis of platelet, monocyte, neutrophil, and lymphocyte counts obtained from peripheral blood samples taken on the first day of treatment. PIV is calculated using the following formula: PIV = T × M × N ÷ L. A receiver operating characteristic (ROC) analysis was employed to identify the optimal cut-off value for PIV about progression-free survival (PFS) and overall survival (OS) outcomes. The primary and secondary endpoints were the differences in OS and PFS between the PIV groups. The Kaplan‒Meier method was used for survival analyses.The ROC analysis indicated that the optimal PIV threshold was 545.5, which exhibited a significant interaction with PFS and OS outcomes. Patients were subsequently divided into two groups based on their PIV levels: a low PIV (L-PIV) group comprising 45 patients and a high PIV (H-PIV) group comprising 44 patients. A comparative analysis of survival rates indicated that patients with elevated PIV had a shorter median PFS of 4.0 months compared to 8.0 months in the low PIV group (P = 0.797), as well as a reduced median OS of 19.0 months versus not available (NA) in the low PIV group (P = 0.215).Our study results did not reveal a statistically significant association between H-PIV measurements and reduced PFS or OS. However, PIV effectively stratified newly diagnosed high-grade glioma patients into two distinct groups with significantly different PFS and OS outcomes.© 2024. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).